FARMERS & MERCHANTS TRUST Co OF LONG BEACH Has $235,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

FARMERS & MERCHANTS TRUST Co OF LONG BEACH lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,226 shares of the medical equipment provider’s stock after selling 529 shares during the quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Zimmer Biomet were worth $235,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after buying an additional 125,852 shares in the last quarter. M&T Bank Corp grew its holdings in shares of Zimmer Biomet by 48.4% during the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock valued at $2,884,000 after purchasing an additional 8,709 shares during the last quarter. National Pension Service increased its position in Zimmer Biomet by 3.8% during the 3rd quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock worth $39,893,000 after purchasing an additional 13,612 shares in the last quarter. Peddock Capital Advisors LLC bought a new position in Zimmer Biomet in the 4th quarter valued at approximately $654,000. Finally, River Global Investors LLP boosted its position in Zimmer Biomet by 31.3% in the third quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock valued at $2,276,000 after buying an additional 5,030 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ZBH. BTIG Research dropped their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. Truist Financial lifted their price target on Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Wells Fargo & Company raised their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Barclays reduced their target price on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a report on Thursday, December 12th. Finally, Raymond James cut their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $123.33.

Zimmer Biomet Stock Up 0.7 %

Shares of NYSE ZBH opened at $109.65 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $100.67 and a 12-month high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The firm has a market cap of $21.83 billion, a PE ratio of 20.85, a P/E/G ratio of 1.79 and a beta of 1.02. The company’s fifty day simple moving average is $107.81 and its 200 day simple moving average is $107.97.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same period last year, the business posted $1.65 EPS. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.